13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-06-25 Event 2026-06-18 SEC 0001193125-26-282713 →

PERCEPTIVE ADVISORS LLC Kardigan, Inc. KARD

Stake: 8.90% Shares: 8,254,144 CUSIP: 485925101 Class: Common Stock, par value $0.00001 per share

Item 4 — Purpose of Transaction

The Reporting Persons acquired the shares of Common Stock set forth in Item 5(c) and hold their shares of Common Stock for investment purposes. Douglas Giordano serves as a member of the Issuer's board of directors, and is a Managing Director at Perceptive Advisors. Each Reporting Person expects to continuously review such person's investment in the Issuer and, depending on various factors including but not limited to, the price of the shares of Common Stock, the terms and conditions of the transaction, prevailing market conditions and such other considerations as such Reporting Person deems relevant, may at any time or from time to time, and subject to any required regulatory approvals, acquire additional shares of Common Stock, preferred stock or other securities convertible into or exercisable or exchangeable for Common Stock from time to time on the open market, in privately- negotiated transactions, directly from the Issuer, or upon the exercise or conversion of securities convertible into or exercisable or exchangeable for Common Stock. Each Reporting Person also may, at any time, subject to compliance with applicable securities laws and regulatory requirements dispose or distribute some or all of its or his Common Stock or such other securities as it or he owns or may subsequently acquire depending on various factors, including but not limited to, the price of the shares, the terms and conditions of the transaction and prevailing market conditions, as well as the liquidity and diversification objectives. Consistent with their investment intent, each Reporting Person may from time to time discuss with the Issuer's management, directors, other shareholders and others, the Issuer's performance, business, strategic direction, capital structure, product development program, prospects and management, as well as various ways of maximizing stockholder value, which may or may not include extraordinary transactions. Except as indicated herein, no Reporting Person, as a stockholder of the Issuer, has any plans or proposals that relates or would result in any of the transactions or other matters specified in clauses (a) through (j) of Item 4 of Schedule 13D. Each Reporting Person may, at any time and from time to time, review or reconsider its or his position and/or change its or his purpose and/or formulate plans or proposals with respect thereto. The information set forth in Item 6 below is incorporated by reference to this Item 4.

Cross-References

Insider Activity (last 365d)
37 transactions
13 buys · 0 sales · 0 awards/exercises
Issuer Cluster
3 13D/G filings on this issuer
2 other filings besides this one
Filer Track Record
28 filings by this filer
27 other filings in the data moat
Short Interest · settle 2026-07-15
DTC 3.81
1,670,728 shares short · +13.7% vs prior

Post-Filing Returns · since 2026-06-18 on KARD

+1 day
0.0%
+5 days
0.0%
+30 days
-10.2%
+60 days
+90 days
+180 days

Anchor price 23.83 on closest trading day on/after 2026-06-18. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-06-22 HRTG GPE, LLC 10%+ owner Buy 3,125,000 $16.00 $50.00M
2026-06-22 BERNS PAUL L director, 10%+ owner Buy 1,250,000 $16.00 $20.00M
2026-06-22 ARCH Venture Partners XIII, LLC director, 10%+ owner Buy 1,250,000 $16.00 $20.00M
2026-06-17 HRTG GPE, LLC 10%+ owner C 2,050,166
2026-06-17 HRTG GPE, LLC 10%+ owner C 6,150,502
2026-06-17 HRTG GPE, LLC 10%+ owner C 3,242,993
2026-06-17 HRTG GPE, LLC 10%+ owner C 2,348,373
2026-06-17 HRTG GPE, LLC 10%+ owner C 1,287,146
2026-06-17 HRTG GPE, LLC 10%+ owner C 3,861,440
2026-06-17 HRTG GPE, LLC 10%+ owner C 2,036,033
2026-06-17 HRTG GPE, LLC 10%+ owner C 1,474,368
2026-06-17 ARCH Venture Partners XIII, LLC director, 10%+ owner C 13,792,035
2026-06-17 ARCH Venture Partners XIII, LLC director, 10%+ owner C 5,148,587
2026-06-17 ARCH Venture Partners XIII, LLC director, 10%+ owner C 1,204,000
2026-06-17 ARCH Venture Partners XIII, LLC director, 10%+ owner C 2,306,401
2026-06-17 Pasternak Andy officer Award 79,640
2026-06-17 Meeker David P director Award 20,706
2026-06-17 BERNS PAUL L director, 10%+ owner C 13,792,035
2026-06-17 BERNS PAUL L director, 10%+ owner Award 20,706
2026-06-17 BERNS PAUL L director, 10%+ owner C 5,148,587
2026-06-17 BERNS PAUL L director, 10%+ owner C 1,204,000
2026-06-17 BERNS PAUL L director, 10%+ owner C 2,306,401
2026-06-17 Moriarty John B officer Award 47,784
2026-06-17 Jahn Brianne officer Award 79,640
2026-06-17 Popovits Kimberly J director Award 20,706
Showing 25 of 37

Other 13D/G Filings on Kardigan, Inc.

FiledFormFilerStakeShares
2026-06-29 SCHEDULE 13D ARCH Venture Fund XIII, L.P. 16.20% 15,042,035 view →
2026-06-29 SCHEDULE 13G HRTG GPE, LLC view →

Other Filings by PERCEPTIVE ADVISORS LLC

FiledFormIssuerStakeShares
2026-07-23 SCHEDULE 13G Freenome, Inc. view →
2026-07-20 SCHEDULE 13G Research Alliance Corporation IV view →
2026-01-26 SCHEDULE TRINITY BIOTECH PLC TRIB 9.90% 1,463,058,248 view →
2026-01-02 SCHEDULE MeiraGTx Holdings plc MGTX 12.90% 10,441,562 view →
2025-02-21 SCHEDULE Solid Biosciences Inc. SLDB 15.60% 11,934,679 view →
2025-02-14 SCHEDULE TRINITY BIOTECH PLC TRIB 20.90% 85,800,000 view →
2025-01-31 SCHEDULE Nautilus Biotechnology, Inc. NAUT 10.00% 12,594,211 view →
2023-10-17 SC Cerevel Therapeutics Holdings, Inc. view →
2023-06-06 SC SOLENO THERAPEUTICS INC SLNO view →
2023-05-30 SC SOLENO THERAPEUTICS INC SLNO view →
2023-05-25 SC SOLENO THERAPEUTICS INC SLNO view →
2023-04-25 SC Cerevel Therapeutics Holdings, Inc. view →
2022-12-06 SC Solid Biosciences Inc. SLDB view →
2022-07-01 SC Athira Pharma, Inc. LONA view →
2022-04-14 SC Lyra Therapeutics, Inc. LYRA view →
2022-03-02 SC AMICUS THERAPEUTICS, INC. FOLD view →
2021-06-25 SC CATABASIS PHARMACEUTICALS INC view →
2021-04-06 SC Landos Biopharma, Inc. view →
2021-03-23 SC Solid Biosciences Inc. SLDB view →
2020-12-17 SC Solid Biosciences Inc. SLDB view →
Showing 20 of 27

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →